“Our Mission: Developing Superior Protection from Pulmonary Embolisms"

Crux Biomedical, Inc., was formed in 2004 by physicians Tom Fogarty and Frank Arko based upon their observations of the clinical limitations of current vena cava filters.

Crux has been awarded five US patents (7,582,100, 7,785,343, 7,789,892, 7,854,747, 8,226,679) for its filter technology, and has FDA Clearance and CE Mark approval for the Crux VCF System.

In December 2012, Crux was acquired by Volcano Corporation.

---

"We just look at where there's a need and     ask ourselves if we can do something." - T. Fogarty, MD World Renowned Surgeon / Inventor / Founder Crux Biomedical

Tom Fogarty, former Stanford University Professor and cardiovascular surgeon, has founded over 33 medical device companies and has been credited with over 125 patents. It has been estimated that Dr. Fogarty’s medical devices have touched the lives of over 25 million patients worldwide.